Serina Therapeutics SER Income Statement (2017-2026)

NYSE SER
$2.65 +0.00 (+0.04%)
As of: Aug 21, 2026 · 12:53 PM EDT
Income Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Revenue & cost
Revenue (Quarter)
0.04M0.02M0.16M0.01M0.01M0.01M0.01M0.03M0.01M0.03M3.09M0.01M0.05M0.01M-0.01M0.13M
Cost of Revenue (Quarter)
0.01M0.00M0.00M0.00M0.01M0.01M0.00M0.00M0.01M0.03M0.00M
Gross Profit (Quarter)
0.02M0.02M0.03M0.00M0.01M0.00M0.01M0.01M0.00M0.03M0.06M
Operating items
Research & Development (Quarter)
0.48M0.28M0.38M0.40M0.26M0.16M0.21M0.40M0.48M0.60M0.91M1.11M1.59M2.42M2.37M2.95M3.15M3.65M3.40M3.82M
Selling, General & Administrative (Quarter)
1.75M1.42M1.52M1.66M1.34M1.39M1.58M0.59M0.47M0.89M1.94M1.22M2.32M2.91M3.17M2.91M2.54M2.74M2.81M2.97M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
2.23M1.70M1.89M2.06M1.60M1.55M1.79M0.99M0.95M1.49M2.85M2.33M3.92M5.33M5.54M5.86M5.70M6.39M6.21M6.78M
Operating Income (Quarter)
-2.21M-1.67M-1.87M-2.05M-1.59M-1.55M-1.78M-0.96M-0.94M-1.46M0.24M-2.32M-3.87M-5.31M-5.55M-5.86M-5.57M-6.39M-6.21M-6.78M
EBIT (Quarter)
-2.21M-1.67M-1.87M-2.05M-1.59M-1.55M-1.78M-0.96M-0.94M-1.46M0.24M-2.32M-3.87M-5.31M-5.55M-5.86M-5.57M-6.39M-6.21M-6.78M
Non-operating items
Other Non Operating Income (Quarter)
0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.10M0.09M0.09M0.06M0.04M0.04M0.05M0.07M0.04M-0.10M0.23M
Non Operating Income (Quarter)
-0.27M-0.28M-0.29M-0.66M-1.03M-0.89M-0.98M2.62M1.75M3.21M0.81M-12.69M9.04M6.70M2.80M1.04M-0.90M1.80M2.89M0.43M
Net income details
EBT (Quarter)
-2.48M-1.96M-2.26M-2.71M-2.62M-2.44M-1.78M-1.05M-1.05M-1.56M0.43M-3.00M-4.48M-5.43M-5.91M-6.29M-5.96M-6.42M-6.38M-8.73M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-2.47M-1.96M-2.25M-2.71M-2.62M-2.44M-2.70M1.66M0.81M1.75M1.05M-15.02M5.18M1.38M-2.74M-4.82M-6.46M-4.59M-3.59M-6.36M
Income from Non-Controlling Interests (Quarter)
0.00M-0.00M-0.00M-0.06M-0.01M-0.01M-0.03M-0.03M-0.01M-0.01M-0.01M-0.01M
Income from Continuing Operations (Quarter)
-2.48M-1.96M-2.26M-2.71M-2.62M-2.44M-1.78M-1.05M-1.05M-1.56M0.43M-3.00M-4.48M-5.43M-5.91M-6.29M-5.96M-6.42M-6.38M-8.73M
Consolidated Net Income (Quarter)
0.01M-0.01M-2.71M-2.62M-2.44M-1.78M-1.05M-1.05M-1.56M0.43M-3.00M-4.48M-5.43M-5.91M-6.29M-5.96M-6.42M-6.38M-8.73M
Income towards Parent Company (Quarter)
0.01M-0.01M-2.71M-2.62M-2.44M-1.78M-1.05M-1.05M-1.56M0.43M-3.00M-4.48M-5.43M-5.91M-6.29M-5.96M-6.42M-6.38M-8.73M
Net Income towards Common Stockholders (Quarter)
0.01M-0.01M-2.71M-2.62M-2.44M-1.78M-1.05M-1.05M-1.56M0.43M-3.00M-4.48M-5.43M-5.91M-6.29M-5.96M-6.42M-6.38M-8.93M
Additional items
EPS (Basic) (Quarter)
0.01-0.01-2.51-0.00M-2.26-1.65-0.97-975.90-0.00M403.15-1.08-526.43-0.61-0.80-0.64-0.60-0.62-0.63-0.55
EPS (Diluted) (Quarter)
0.01-0.01-2.51-0.00M-0.00M-0.00M-0.12-975.90-0.00M403.15-1.08-441.27-0.50-0.80-0.64-0.60-0.62-0.63-0.55
Shares Outstanding (Quarter)
1.08M1.08M1.08M1.08M0.00M1.08M1.08M1.08M0.00M0.00M0.00M2.79M0.01M8.85M7.36M9.76M10.00M10.34M10.19M16.39M
Shares Outstanding (Diluted) (Quarter)
1.07M1.07M1.07M1.08M0.00M0.00M0.00M8.57M0.00M0.00M0.00M2.79M0.01M10.75M7.36M9.76M10.00M10.34M10.19M16.39M
Shares Outstanding (Entity) (Quarter)
1.08M1.08M1.08M1.08M0.00M1.08M1.08M1.08M0.00M0.00M0.00M2.79M0.01M8.89M7.36M9.93M10.14M10.54M10.77M16.39M
EBITDA (Quarter)
-2.21M-1.67M-1.87M-2.05M-1.59M-1.55M-1.78M-0.96M-0.94M-1.46M0.24M-2.32M-3.87M-5.31M-5.55M-5.86M-5.57M-6.39M-6.21M-6.78M
Interest Expenses (Quarter)
0.00M0.28M0.57M0.86M0.92M0.09M0.11M0.10M-0.19M0.68M0.62M0.12M0.36M0.43M0.39M0.02M0.17M1.95M
Tax Rate (Quarter)